BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
| Revenue (TTM) | $6.61B |
| Gross Profit (TTM) | $5.91B |
| EBITDA | $1.35B |
| Operating Margin | 22.20% |
| Return on Equity | 18.40% |
| Return on Assets | 8.42% |
| Revenue/Share (TTM) | $59.12 |
| Book Value | $50.95 |
| Price-to-Book | 7.57 |
| Price-to-Sales (TTM) | 7.01 |
| EV/Revenue | 6.56 |
| EV/EBITDA | 29.83 |
| Quarterly Earnings Growth (YoY) | 212.50% |
| Quarterly Revenue Growth (YoY) | 33.80% |
| Shares Outstanding | $104.92M |
| Float | $81.33M |
| % Insiders | 17.28% |
| % Institutions | 32.80% |
Volatility is currently expanding
BeOne Medicines NASDAQ: ONC raised its 2026 revenue and operating income forecasts after third-quarter sales of its cancer drug BRUKINSA topped $1 billion in the United States for the first time.
BeOne Medicines AG ( ONC ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Daniel Maller - Vice President of Investor Relations John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - Chief Financial Officer Lai Wang Amit Agarwal - Chief Medical Officer of Hematology Mark Lanasa - Senior VP & Chief Medical Officer for Solid Tumors Matthew Shaulis - General Manager of North America Xiaobin Wu Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Sean Laaman - Morgan Stanley, Research Division Andrew Berens - Leerink Partners LLC, Research Division Gregory Renza - Truist Securities, Inc., Research Division Yaron Werber - TD Cowen, Research Division Ziyi Chen - Goldman Sachs Group, Inc., Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, everyone. Welcome to BeOne Medicines Q3 2026 Earnings Call webcast.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained respo.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. An archived webcast will be available on the Company's website. About BeOne Me.
HPE, AER, UGP, ONC and BWFG have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2026.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GE.
BeOne Medicines AG is a fast-growing oncology company and a Wall Street favorite. Tevimbra, its PD-1 inhibitor, helped drive growth, with Q2 revenue rising 10.8% QoQ and 18.1% YoY to $228.5 million. BeOne's rich pipeline includes BGB-B2033, BG-C477, and BGB-58067, with clinical data scheduled for presentation at the 2026 ESMO Congress, taking place October 23-27.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com.To ensure a.
BeOne Medicines Ltd. - Sponsored ADR (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ONC and any ticker you trade — then tracks every position and per-strategy win rate.
